Abstract
Clonal populations of cells continuously evolve new genetic diversity, but it takes a significant amount of time for the progeny of a single cell with a new beneficial mutation to outstrip both its ancestor and competitors to fully dominate a population. If genotypes with these driver mutations can be discovered earlier—while they are still extremely rare—it may be possible to anticipate the future evolution of these populations. For example, one could diagnose the likely course of incipient diseases, such as cancer and bacterial infections, and better judge which treatments will be effective, by tracking rare drug-resistant variants. To test this approach, we replayed the first 500 generations of a >70,000-generation Escherichia coli experiment and examined the trajectories of new mutations in eight genes known to be under positive selection in this environment in six populations. By employing a deep sequencing procedure using molecular indexes and target enrichment we were able to track 236 beneficial mutations at frequencies as low as 0.01% and infer selection coefficients for 180 of these. Distinct molecular signatures of selection on protein structure and function were evident for the three genes in which beneficial mutations were most common (nadR, pykF, and topA). We detected mutations hundreds of generations before they became dominant and tracked beneficial alleles in genes that were not mutated in the long-term experiment until thousands of generations had passed. Therefore, this targeted adaptome sequencing approach can function as an early warning system to inform interventions that aim to prevent undesirable evolution.
Competing Interest Statement
J.E.B. is the owner of Evolvomics LLC. D.E.D. has been a paid consultant for Evolvomics LLC.
Footnotes
Data Availability Statement: DNA sequence files are available from the NCBI Sequence Read Archive (accession number PRJNA601748). Code and processed data files are available on GitHub (https://github.com/barricklab/adaptome-capture).
Funding: This work was supported by the Cancer Prevention & Research Institute of Texas (CPRIT) (RP130124), the National Institutes of Health (R00-GM087550), the National Science Foundation (CBET-1554179 and DEB-1813069), and the NSF BEACON Center for the Study of Evolution in Action (DBI-0939454). D.E.D. acknowledges support from a University of Texas at Austin CPRIT research traineeship (RP101501). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: J.E.B. is the owner of Evolvomics LLC. D.E.D. has been a paid consultant for Evolvomics LLC.